Intellipharmaceutics International Inc. (IPCI)

[doogdilinger]

Can Intellipharmaceutics International Inc. (NASDAQ:IPCI) Meet Analysts Expectations?

By Stocks Daily Staff -
June 18, 2016

The research entity Zacks released its research report on Intellipharmaceutics International Inc. (NASDAQ:IPCI) as per which its stock can move to hit $12 in the approaching fiscal.

Zacks polled 3 several brokerages and thereafter released an estimated price target of $8.666 on the stock. These brokerages have fixed the 12-month price targets, and the bearish price target is set at $6. The brokerages apply individual rating process to compile research reports. Some firms assign sell; some buy while some put hold ratings. On the other hand, Zacks practice a different mechanism wherein, it analyzes the different analysts views, calculate the mean and place a rating on a ‘1-5’ scale. Such kind of rating is named as the ‘Average Brokerage Recommendation’. Investors are positive on the stock when ABR is ‘1’ while they are bearish on the stocks with ABR of ‘5’.

Intellipharmaceutics International Inc. (NASDAQ:IPCI) has a rating of 1.43. Here it is imperative to mention that there are various parameters applied for obtaining a stock rating. One of the prime factors analyzed is firm’s fiscal report. It chiefly directs the stock’s price direction.

For the quarter completed on 2016-02-29, Intellipharmaceutics International Inc. (NASDAQ:IPCI) posted EPS of $-0.07. The earnings were $-0.02 below than the predicted numbers by Zacks, highlighting an unexpected difference of -28.57%. For the impending three-month period, the street is predicting the firm to register EPS of $-0.07, representing views of 3 brokerages.
http://www.stocksdaily.net/can-intellipharmaceutics-international-inc-nasdaqipci-meet-analysts-expectations-4/103810/